Multiobjective V H H discovery through integrated high-throughput screening and AlphaFold3-guided structural prioritization
Authors:
- Max D. OverathMOMax D. Overath
- Suthimon ThumtechoSTSuthimon Thumtecho
- Esperanza Rivera-De-TorreEsperanza Rivera-De-Torre
- Melisa Benard-ValleMBMelisa Benard-Valle
- Darian S. WolffDWDarian S. Wolff
- Rahmat GrahadiRGRahmat Grahadi
- Kasper H. BjörnssonKBKasper H. Björnsson
- Nils HofmannNHNils Hofmann
- Jann LedergerberJLJann Ledergerber
- Anne LjungarsALAnne Ljungars
- Andreas H. LaustsenAndreas H. Laustsen
- 2 October 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Abstract
Finding therapeutic antibodies that bind multiple related targets with high affinity and favorable biophysical properties remains challenging and resource-intensive. For snakebite antivenoms, this challenge is critical as treatments must neutralize toxins across multiple snake species. We developed a pipeline combining high-throughput yeast screening, deep sequencing, and AlphaFold3 structure prediction to identify polyspecific variable domains of heavy chain–only antibodies (V H Hs) against long-chain α-neurotoxins. Multiplexed yeast display screening generated a dataset of diverse hits with varying binding specificities. AlphaFold3-generated V H H-toxin complex predictions enabled stringent high-precision structural triage of polyspecific V H Hs that bind conserved epitopes across multiple toxins, with a representative subset experimentally confirmed to block toxin binding to the acetylcholine receptor. These structural insights provided a starting point for computational optimization of affinity and soluble expression of the V H Hs, with experimental validation confirming that optimized V H H variants maintained broad binding specificity across toxins. This integrated approach supports structure-guided prioritization of polyspecific V H H hits, offering a high-precision filter that could reduce future reliance on extensive experimental specificity screening and providing a framework applicable to other therapeutic contexts, in which substantial antigen variation occurs and broad neutralization is essential.Keywords
Funding Information
- Wellcome Trust (221702/Z/20/Z)
- Ananda Mahidol Foundation
- Danmarks Frie Forskningsfond (5332-00023B)
- Novo Nordisk USA
- Knut and Alice Wallenberg Foundation
- Villum Foundation (00025302)
- Independent Research Fund Denmark (grant 10.46540/4283-00192B)
- European Union’s Horizon (850974)
- Eurotech University Allicance programme
- Eurotech University Allicance programme
This publication has 51 references indexed in Scilit:
- Synthetic coevolution reveals adaptive mutational trajectories of neutralizing antibodies and SARS-CoV-2Cell Systems, 2025
- Applications of machine learning in antibody discovery, process development, manufacturing and formulation: Current trends, challenges, and opportunitiesComputers & Chemical Engineering, 2024
- Synthetic antibodies block receptor binding and current‐inhibiting effects of α‐cobratoxin from Naja kaouthiaProtein Science, 2022
- Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody DiscoveryTrends in Biotechnology, 2021
- Recombinant Antibody Selections by Combining Phage and Yeast Display2018
- Pros and cons of different therapeutic antibody formats for recombinant antivenom developmentToxicon, 2018
- Bioinformatic and Statistical Analysis of Adaptive Immune RepertoiresTrends in Immunology, 2015
- Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxinsToxicon, 2015
- Unveiling the nature of black mamba (Dendroaspis polylepis) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom developmentJournal of Proteomics, 2015
- The CamSol Method of Rational Design of Protein Mutants with Enhanced SolubilityJournal of Molecular Biology, 2015